CME INFORMATION

TARGET AUDIENCE
Medical Oncologists

GLOBAL LEARNING OBJECTIVES:
Upon completion of this activity participants should be able to:

• Critically evaluate the clinical implications of emerging clinical trial data, patterns of care data and patients’ perspectives on breast cancer treatment decisions.
• Counsel women with low-risk invasive disease about the absolute risks and benefits of adjuvant systemic chemotherapy, and describe the potential utility of a predictive assay to help guide these discussions.
• Counsel postmenopausal patients with ER-positive breast cancer about the risks and benefits of adjuvant aromatase inhibitors and about switching or sequencing aromatase inhibitors after tamoxifen.
• Counsel premenopausal women about the risks and benefits of adjuvant ovarian ablation in combination with tamoxifen or aromatase inhibition.
• Distinguish the risk-to-benefit profiles of chemotherapeutic agents and combinations to determine a management algorithm for women with metastatic breast cancer.
• Develop and explain a management strategy for therapy in patients with ER-positive metastatic disease including sequencing of hormonal therapies.
• Describe and implement an algorithm for treatment of patients with HER2- positive breast cancer.

EVALUATION STATEMENT:
An evaluation form will be given to each participant at the conclusion of this activity.

ACCREDITATION STATEMENT:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT:
Research To Practice designates this educational activity for a maximum of 6.5 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

EDUCATIONAL SUPPORT:
This event is supported by education grants from AstraZeneca Pharmaceuticals LP and Roche Laboratories Inc.